3rd Nov 2015 08:46
LONDON (Alliance News) - Advanced Medical Solutions Group PLC on Tuesday said it has received US Food and Drug Administration approval for two new product claims for its topical skin adhesive octyl formulation product LiquiBand Exceed.
The woundcare specialist said the claims will allow it to differentiate LiquiBand Exceed around wound coverage, yield and reuse, providing clinicians with the ability to increase the usage of a single applicator, saving time and cost.
The two new claims include the use of a single device to cover wounds of up to 30cm, as well as a single device being suitable for intraoperative reuse for up to 90 minutes on a single patient.
The formula in LiquiBand Exceed means that the adhesive polymerises via skin contact using naturally occurring skin moisture, meaning that the applicator device does not dry out. In-vitro testing also proved the device could continually express glue in intervals for up to 90 minutes after device activation, Advanced Medical said.
"LiquiBand Exceed has been an excellent addition to our LiquiBand topical skin adhesive portfolio demonstrating encouraging initial uptake since its launch this year. These extended US product claims will help us to continue to provide a superior product for clinicians and a versatile solution for healthcare providers in this key market, in which we are focused on growing our market share," Chief Executive Chris Meredith said.
Shares in Advanced Medical were trading up 5.8% at 177.25 pence Tuesday morning.
By Karolina Kaminska; [email protected] @KarolinaAllNews
Copyright 2015 Alliance News Limited. All Rights Reserved.
Related Shares:
Advanced Medical Solutions Group